title: Gemtuzumab ozogamicin exposure and portal fibrosis.
authors.forename: Robin
authors.initials: R
authors.lastname: Perry
authors.forename: Jamie
authors.initials: J
authors.lastname: Penk
authors.forename: Neena
authors.initials: N
authors.lastname: Kapoor
authors.forename: Ami J
authors.initials: AJ
authors.lastname: Shah
mesh_terms: D000617:Aminoglycosides / Q000009:adverse effects*; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D056486:Chemical and Drug Induced Liver Injury; D002648:Child; D002675:Child, Preschool; D005260:Female; D005355:Fibrosis; D000079982:Gemtuzumab; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D015473:Leukemia, Promyelocytic, Acute / Q000188:drug therapy*; D008297:Male; D011169:Portal Vein / Q000473:pathology*; D012008:Recurrence
chemical_list: D000617:Aminoglycosides; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000079982:Gemtuzumab